Beyond the four ‘majors’ in terms of cancer conferences (AACR, ASCO, ESMO, and ASH) there are a large number of others too numerous to mention and even a growing number of specialist meetings organised around various subtopics or niches.
The Covid–19 debacle has a silver lining in that it has created a great opportunity to dip into meetings or events one wouldn’t otherwise be able to attend due to geography or logistics.
Personally, I’ve been sincerely grateful for the new learning opportunities this unique microcosm has provided and am happy to share some new scientific or clinical findings or even emerging trends we at BSB have come across during the strange year 2020 has turned out to be.
Nothing can replace face to face interactions with people, yet out of despair springs hope eternal… especially on US Election Day.
There’s a lot going on under the hood in terms of what various academic and company researchers alike are doing in cancer research, so as we wait for SITC next week, I wanted to spend some time highlighting some important developments I learned about from recent specialist meetings, which will likely appeal to both pharma and biotech execs, as well as those folks looking to invest in early scientific opportunities before they become too mainstream….